journal article·2018-11-05

Improved anticancer efficacy of epirubicin by magnetic mesoporous silica nanoparticles:in vitroandin vivostudies

Legha Ansari, Mahmoud Reza Jaafari, Tahereh Rohani Bastami, Bizhan Malaekeh-Nikouei

Publisher page

Abstract

The development of magnetic nanoparticles as delivery carriers to magnetically accumulate anticancer drug in cancer tissue has attracted immense interest. In the present study, magnetic mesoporous silica nanoparticles (MMSNs) with magnetite core and silica shell were synthesized. The obtained MMSNs were characterized by DLS, XRD, FT-IR, TEM and VSM in order to investigate the nanoparticle characteristics. With the focus on in vivo validation of such magnetic drug delivery systems, we selected epirubicin (EPI) as the drug. The anticancer properties of EPI-loaded MMSNs were evaluated in a C-26 colon carcinoma model. Alongside monitoring of drug in the tissues with animal imaging system, the tissue distribution was also determined quantitavely. The average size of MMSNs determined with TEM images was about 18.68 ± 2.31 nm. The cellular uptake test indicated that geometric mean fluorescence intensity (MFI) of cells treated with MMSN + EPI in presence of external magnetic field was increasing 27% compared with free EPI. In addition, treatment with drug-loaded MMSNs with the aid of external magnetic gradient had significantly higher inhibition efficacy towards tumor growth than the free EPI treated mice. The targeted drug delivery through external magnet-attraction using EPI-loaded MMSNs resulted in high tumor cell uptake, which leads to elimination of cancer cells effectively.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Quantum Dots Synthesis And Properties · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Nanotechnology Research Center, Institute of Pharmaceutical Technology, Mashhad University of Medical Sciences, Mashhad, Iran;

Biotechnology Research Center, Institute of Pharmaceutical Technology, Mashhad University of Medical Sciences, Mashhad, Iran;

Department of Chemical Engineering, Faculty of Engineering, Quchan University of Advanced Technology, Quchan, Iran

Funding

Mashhad University of Medical Sciences

References (55)

Show source-provided references
1. 10.1016/j.biomaterials.2004.03.01610.1016/j.biomaterials.2004.03.016 ↗
2. Schwertmann U · 2008
3. 10.1016/S0022-4596(05)80258-010.1016/S0022-4596(05)80258-0 ↗
4. 10.1088/0953-8984/23/12/12600310.1088/0953-8984/23/12/126003 ↗
5. 10.1021/cr950235710.1021/cr9502357 ↗
6. Salzman E. · Am J Soc Artif Intern Organs · 1983 · 6 · 6010.1177/039139888300600202 ↗
7. Yu J-H · Rev Adv Mater Sci · 2003 · 4 · 5510.1016/S1468-6996(03)00007-X ↗
8. 10.1021/jp907046f10.1021/jp907046f ↗
9. 10.1021/cr300068p10.1021/cr300068p ↗
10. 10.1038/srep2054310.1038/srep20543 ↗
11. Sadeghnia HR · Toxicol Mech Methods · 2015 · 25 · 433
12. 10.1021/ja206998x10.1021/ja206998x ↗
13. 10.1039/c2cs15308d10.1039/c2cs15308d ↗
14. 10.1080/21691401.2018.144394110.1080/21691401.2018.1443941 ↗
15. Gupta MN · Artif Cells Nanomed Biotechnol · 2011 · 39 · 98
16. 10.1016/j.jconrel.2016.10.02110.1016/j.jconrel.2016.10.021 ↗
17. 10.1080/02656736.2016.124373610.1080/02656736.2016.1243736 ↗
18. 10.1016/j.biomaterials.2015.10.05310.1016/j.biomaterials.2015.10.053 ↗
19. 10.1002/adfm.20130334510.1002/adfm.201303345 ↗
20. 10.1007/s12274-014-0541-910.1007/s12274-014-0541-9 ↗
21. 10.1021/la700883y10.1021/la700883y ↗
22. 10.1063/1.165881210.1063/1.1658812 ↗
23. 10.1016/j.ultsonch.2012.01.01210.1016/j.ultsonch.2012.01.012 ↗
24. 10.1021/acs.molpharmaceut.5b0086610.1021/acs.molpharmaceut.5b00866 ↗
25. 10.2174/156720181366615123109405610.2174/1567201813666151231094056 ↗
26. 10.1039/c2nr30352c10.1039/c2nr30352c ↗
27. Hanafi-Bojd MY · Nanomed J · 2017 · 4 · 135
28. 10.1002/jps.2352210.1002/jps.23522 ↗
29. 10.1016/j.jconrel.2012.06.02810.1016/j.jconrel.2012.06.028 ↗
30. 10.1007/s00432005016010.1007/s004320050160 ↗
31. 10.1073/pnas.060175510310.1073/pnas.0601755103 ↗
32. 10.1016/j.jconrel.2015.10.04410.1016/j.jconrel.2015.10.044 ↗
33. 10.1158/1078-0432.CCR-05-156610.1158/1078-0432.CCR-05-1566 ↗
34. Huang SK · Cancer Res · 1992 · 52 · 6774
35. 10.1016/j.ijpharm.2013.10.01810.1016/j.ijpharm.2013.10.018 ↗
36. 10.1002/anie.20090011110.1002/anie.200900111 ↗
37. 10.1186/2045-3701-4-710.1186/2045-3701-4-7 ↗
38. Skoog DA · 2013
39. 10.1088/0957-4484/20/48/48560110.1088/0957-4484/20/48/485601 ↗
40. Xue S · Intl J Nanomed · 2014 · 9 · 2527
41. 10.1021/acs.analchem.6b0303410.1021/acs.analchem.6b03034 ↗
42. 10.1007/s10971-006-9321-710.1007/s10971-006-9321-7 ↗
43. 10.4172/2157-7439.100024410.4172/2157-7439.1000244 ↗
44. 10.1016/j.phrs.2009.12.01210.1016/j.phrs.2009.12.012 ↗
45. 10.1016/j.ejpb.2014.12.00910.1016/j.ejpb.2014.12.009 ↗
46. Knežević NŽ · Adv Mater Sci Engg · 2015 · 2015 · 567350
47. 10.1021/nn101511710.1021/nn1015117 ↗
48. 10.1007/s00232-010-9271-410.1007/s00232-010-9271-4 ↗
49. Weigel P · J Biologic Chem · 1981 · 256 · 261510.1016/S0021-9258(19)69656-0 ↗
50. 10.1158/1078-0432.CCR-09-319910.1158/1078-0432.CCR-09-3199 ↗
51. 10.1016/j.biomaterials.2016.05.03010.1016/j.biomaterials.2016.05.030 ↗
52. 10.1002/adma.20140015810.1002/adma.201400158 ↗
53. 10.2165/00003088-199426060-0000210.2165/00003088-199426060-00002 ↗
54. 10.1002/adma.20130123210.1002/adma.201301232 ↗
55. 10.1016/j.biomaterials.2013.05.02810.1016/j.biomaterials.2013.05.028 ↗